Celltrion, Institutional Investors Net Sell 68,603 Shares in Last 5 Days... Stock Price at 293,000 Won (-4.87%)

As of 2:30 PM on the 26th, Celltrion is trading at 293,000 KRW, down 4.87% from the previous day. The trading volume is 808,413 shares, which is 59.57% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.

On February 23, KB Securities researcher Hong Ga-hye stated, "Growth is expected based on the expansion of existing biosimilars, the launch country expansion of Remsima SC, and the European launch of Uplyma (2Q21E). However, there is short-term earnings volatility depending on the development and production schedule of COVID-19 treatments. In particular, the decision on emergency use authorization of Regkirona in the US/Europe (1H21), confirmation of Phase 3 clinical trial results on a large number of patients, and verification of efficacy against the South African variant through cocktail therapy with subsequent substances are expected to be major variables in treatment development." The target price for Celltrion was announced as 360,000 KRW.

Over the past five days, individual investors have net purchased 51,252 shares of Celltrion, while foreigners and institutions have net purchased 13,685 shares and net sold 68,603 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.